Observational studyPloS one2017

Inflammatory Activity on Natalizumab Predicts Short-Term but Not Long-Term Disability in Multiple Sclerosis.

Joel Raffel et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.